Caribou Biosciences Inc., of Berkeley, Calif., granted Oxford Nanopore Ltd., of Oxford, U.K., a worldwide, nonexclusive license under foundational CRISPR/Cas9 intellectual property controlled by Caribou for nanopore sequencing. CRISPR/Cas9-mediated enrichment for nanopore sequencing enables targeted sequencing and is designed to reduce cost, data output and turnaround time.